Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Pharmacy, University of Pisa Via Bonanno 6 56126 Pisa Italy giulia.bononi@farm.unipi.it valentina.citi@unipi.it alma.martelli@unipi.it giulio.poli@unipi.it tiziano.tuccinardi@unipi.it carlotta.granchi@unipi.it lara.testai@unipi.it vincenzo.calderone@unipi.it filippo.minutolo@unipi.it.
Center for Instrument Sharing of the University of Pisa (CISUP) Lungarno Pacinotti 43 56126 Pisa Italy.
Department of Animal Sciences, The Robert H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Rehovot 761001, Israel.
School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, China.
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Implantation of implantable cardioverter-defibrillators (ICD) has increased significantly over the past decade. However, limited data exist regarding practices and policies of ICD implantations in Kaz...
Using the Unified Healthcare Information System database of the entire Kazakh adult population, statistical and cost data of ICD implantations in 2017-2019 were evaluated. Cardiologists and electrophy...
Implantation of traditional transvenous cardioverter-defibrillators for residents of Kazakhstan is fully reimbursed. A total of 2,263 ICD interventions (2,252 new implantations and 11 reimplantations)...
The number of ICD implantation in Kazakhstan is steadily continuing to grow, although, compared to developed countries, the implantation rate especially for S-ICD remains low. There is a need in delib...
Wearable cardioverter-defibrillators (WCD) have emerged as a valuable tool in the management of patients at risk for life-threatening arrhythmias. These devices offer a non-invasive and temporary solu...
From November 2022 to May 2024, we conducted an outpatient follow-up of 41 patients receiving WCD. Regular check-ups, remote monitoring and comprehensive echocardiography were performed to optimise a ...
The average age of the patients was 59.2.4±16.5 years, with 78% being male. Among the cohort, 54% had hypertension, 41% were smokers and 66% had dyslipidaemia, while 27% were diabetic. WCD was assigne...
The use of WCD for patients at high risk of arrhythmias allowed to optimise therapy and limit the indications for ICD. Inappropriate implantation of ICD was avoided in 69% of patients who received WCD...
Lead failure is the major limitation in implantable cardioverter-defibrillator (ICD) therapy. Long-term follow-up data for Biotronik Linox ICD leads are limited. Therefore, we analyzed the performance...
All Linox and Linox Smart ICD leads implanted between 2006 and 2015 were identified. Lead failure was defined as electrical dysfunction (oversensing, abnormal impedance, exit block). Lead survival was...
We included 417 ICD leads. The median follow-up time for Linox (n = 205) was 81 months and for Linox Smart (n = 212) 75 months. During that follow-up time, 30 Linox (14.6%) and 16 Linox Smart leads (7...
This relatively large study with a long follow-up period highlights a relevant failure rate of Biotronik Linox leads. The performance of Linox versus Linox Smart ICD leads was comparable. Although we ...
Cardiovascular disease is the leading cause of morbidity and mortality worldwide. The implementation of effective technologies such as Implantable cardioverter-defibrillator (ICD) for patients at risk...
To assess the economic effectiveness of ICD in comparison with conservative tactics for preventing life-threatening rhythm disturbances in Kazakhstan....
A Markov model was built with a time horizon of 35 years. Mortality and utility data were obtained from the available literature. The economic parameters of the model are based on the approved tariffs...
The total costs in the primary prevention (PP) group by ICD implantation and in the control group were 8,903,786 tenges and 3,194,414 tenges, respectively. The discounted total quality-adjusted life-y...
The ICD for the primary prevention of the development of life-threatening rhythm disturbances and sudden cardiac death is a cost-effective health technology from the position of a payer in the health ...
Defibrillation testing (DFT) is recommended during subcutaneous implantable cardioverter-defibrillator (S-ICD) implantation. Previous studies analyzing the potential interference of propofol with defi...
All patients with S-ICD implantation between 01/2017 and 11/2020 at the University Heart Center Freiburg were retrospectively analyzed. Two groups were generated depending on the success of the first ...
In 12 of the included 80 (15%) patients, first shock during DFT failed. The absolute dose of propofol was significantly higher in patients with first shock failure (median 653 mg [IQR 503-855]) compar...
There is an independent association of propofol dose and first shock failure in routine S-ICD defibrillation testing....
The extravascular implantable cardioverter-defibrillator (ICD) has a single lead implanted substernally to enable pause-prevention pacing, antitachycardia pacing, and defibrillation energy similar to ...
We conducted a prospective, single-group, nonrandomized, premarket global clinical study involving patients with a class I or IIa indication for an ICD, all of whom received an extravascular ICD syste...
A total of 356 patients were enrolled, 316 of whom had an implantation attempt. Among the 302 patients in whom ventricular arrhythmia could be induced and who completed the defibrillation testing prot...
In this prospective global study, we found that extravascular ICDs were implanted safely and were able to detect and terminate induced ventricular arrhythmias at the time of implantation. (Funded by M...
The manufacturer of subcutaneous implantable cardioverter defibrillators (S-ICDs) acknowledges that 'deep implants' may fail to elicit a magnet response, however, does not define 'deep implant' or rec...
Sunshine Coast University Hospital's S-ICD cohort underwent magnet response evaluation; where bar and donut magnets were compared and the evoked magnet response was recorded in three separate zones, g...
Patients (n = 39) with measurable TD (n = 30) were analyzed. The bar magnet evoked a magnet response in all zones in 53% of patients, compared with 73% of patients with the donut magnet (p = 0.18). Th...
We observed a statistically significant association between TD and ability to evoke magnet response. The bar magnet was less reliable than the donut magnet for therapy inhibition in deep implants....
The subcutaneous implantable-defibrillator (S-ICD) is a relatively new alternative to the transvenous ICD system to minimize intravascular lead-related complications. This paper presents outcome of SI...
Between October 2015 and June 2022, this prospective multicenter national registry included 223 patients with a standard indication for an ICD, who neither required bradycardia pacing nor needed cardi...
The mean age of the patients was 45 ± 17 years. The majority (79.4%) were male. Ischemic cardiomyopathy (39.5%) was the most common underlying disorder among patients selected for S-ICD implant. Most ...
S-ICDs were effective at detecting and treating both induced and spontaneous ventricular arrhythmias. Major clinical complications were rare....
The absence of pacing capabilities may reduce the appeal of subcutaneous implantable cardioverter-defibrillator (S-ICD) devices for patients at risk for conduction disorders or with antitachycardia pa...
The purpose of this study was to investigate the need for a subsequent transvenous (TV) device in patients implanted with an S-ICD and its predictors....
All patients implanted with an S-ICD were enrolled from the multicenter, real-world iSUSI (International SUbcutaneouS Implantable cardioverter defibrillator) Registry. The need for a TV device and its...
A total of 1509 patients were enrolled (age 50.8 ± 15.8 years; 76.9% male; 32.0% ischemic; left ventricular ejection fraction 38% [30%-60%]). Over 26.5 [13.4-42.9] months, 155 (10.3%) and 144 (9.3%) p...
A low rate (2.7%) of conversion from S-ICD to a TV device was observed at follow-up, with need for antibradycardia pacing, ATP, or CRT being the main reasons. BMI >30 kg/m...
The PRAETORIAN score was developed to evaluate the implant position and predict defibrillation success in patients implanted with a subcutaneous implantable cardioverter-defibrillator (S-ICD). However...
We evaluated usefulness of this score, which was determined by width of sub-coil fat, sub-generator fat, and anterior positioning of the S-ICD generator by post-operative chest X-ray, in consecutive 1...
The median PRAETORIAN score was 30 (30-45) and 93 patients were classified as a low risk of conversion failure. The remaining seven were at an intermediate risk. Almost all patients were classified as...
Most Japanese patients were classified as at low risk of conversion failure. The PRAETORIAN score may be useful for the evaluation of conversion failure in Japanese S-ICD implanted patients....
